Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 12, Issue 11, Pages 1589-1598Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.12.11.1589
Keywords
arrhythmia; atrial fibrillation; IKur; Kv1.5; potassium channel blockers
Categories
Ask authors/readers for more resources
Atrial arrhythmias are a common problem in cardiological practice. Despite the availability of several antiarrhythmic drugs there is a medical need for safer and more efficient treatments. The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. This review summarises patents claiming such compounds.-The chemistry and biological data disclosed in these patents are discussed in light of recent work demonstrating the antiarrhythmic effects of Kv1.5 blockers in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available